Physician profile
Xiaoyi Ye
NPI 1821279514
$25,045.07
in general payments reported to CMS, 2019-2025
19 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $1,002 · 2021: $6,328 · 2022: $8,135 · 2023: $7,247 · 2024: $910 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,967 · Food and Beverage: $2,255 · Consulting Fee: $1,434 · Education: $190 · Travel and Lodging: $36.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,967.00 |
| Food and Beverage | $2,254.58 |
| Consulting Fee | $1,434.00 |
| Education | $190.01 |
| Travel and Lodging | $36.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20,336.53 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $821.23 | 2021-2025 | Ultomiris |
| Veloxis Pharmaceuticals, INC. | $691.68 | 2019-2025 | Envarsus |
| Sanofi-Aventis U.S. LLC | $663.60 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $427.14 | 2023-2025 | Terlivaz |
| Astellas Pharma US INC | $410.54 | 2019-2024 | Cresemba |
| Baxter Healthcare | $380.75 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $243.17 | 2022-2024 | Livtencity |
| Astrazeneca Pharmaceuticals LP | $233.44 | 2022-2024 | Farxiga |
| Dynavax Technologies Corporation | $222.53 | 2021-2022 | |
| Gilead Sciences, INC. | $124.80 | 2019 | |
| Vifor Pharma, INC. | $121.95 | 2021 | |
| Allergan, INC. | $120.94 | 2019 | |
| Ardelyx, INC. | $114.69 | 2025 | Xphozah 30 Mg |
| Merck Sharp & Dohme LLC | $55.29 | 2024 | Prevymis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.90 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.01 | 2025 | |
| Eisai INC. | $18.45 | 2020 | |
| Travere Therapeutics, INC. | $4.43 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoyi Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.